Carbapenem Antibiotics Versus Other Antibiotics for Complicated Intra-abdominal Infections: a Systematic Review and Patient-Level Meta-analysis of Randomized Controlled Trials (PROSPERO CRD42018108854).
Abdominal
Antibiotics
Infections
Surgery
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
05
01
2023
accepted:
18
02
2023
medline:
16
6
2023
pubmed:
24
3
2023
entrez:
23
3
2023
Statut:
ppublish
Résumé
The treatment of complicated intra-abdominal infections remains a challenge. Both optimal medical and surgical therapy (i.e., source control) are needed to achieve low mortality and morbidity. The objective of this systematic review and meta-analysis is to determine the impact of carbapenem antibiotic therapy compared to other antibiotics in complicated intra-abdominal infections (secondary peritonitis) with an emphasis on mortality and postoperative complications. A systematic literature search from PubMed/Medline and Web of Science databases was carried out. The last search was conducted in August 2022. PRISMA guidelines were followed. Pre-defined outcomes were mortality, treatment success, treatment failure, and adverse events. Ten randomized controlled trials, published from 1983 to 2013 with a total of 2377 patients (1255 patients in the carbapenem antibiotics group and 1122 in the control group), were identified. A meta-analysis comparing patients undergoing carbapenem antibiotic therapy and patients receiving other antibiotics was performed. No significant difference regarding mortality (OR 1.19, 95% CI [0.79; 1.82], p = 0.40), treatment success (OR 1.17, 95% CI [0.72; 1.91], p = 0.53), and treatment failure (OR 0.84, 95% CI [0.48; 1.45], p = 0.52) was observed. Carbapenem therapy was associated with fewer adverse events compared to therapy with other antibiotics (OR 0.79, 95% CI [0.65; 0.97], p = 0.022). There is currently no evidence that carbapenem antibiotics are superior in terms of mortality, and success or failure for the treatment of complicated intra-abdominal infections (secondary peritonitis). The rate of adverse events is lower under carbapenem therapy compared to control antibiotics. PROSPERO 2018 CRD42018108854.
Sections du résumé
BACKGROUND
The treatment of complicated intra-abdominal infections remains a challenge. Both optimal medical and surgical therapy (i.e., source control) are needed to achieve low mortality and morbidity. The objective of this systematic review and meta-analysis is to determine the impact of carbapenem antibiotic therapy compared to other antibiotics in complicated intra-abdominal infections (secondary peritonitis) with an emphasis on mortality and postoperative complications.
METHODS
A systematic literature search from PubMed/Medline and Web of Science databases was carried out. The last search was conducted in August 2022. PRISMA guidelines were followed. Pre-defined outcomes were mortality, treatment success, treatment failure, and adverse events.
RESULTS
Ten randomized controlled trials, published from 1983 to 2013 with a total of 2377 patients (1255 patients in the carbapenem antibiotics group and 1122 in the control group), were identified. A meta-analysis comparing patients undergoing carbapenem antibiotic therapy and patients receiving other antibiotics was performed. No significant difference regarding mortality (OR 1.19, 95% CI [0.79; 1.82], p = 0.40), treatment success (OR 1.17, 95% CI [0.72; 1.91], p = 0.53), and treatment failure (OR 0.84, 95% CI [0.48; 1.45], p = 0.52) was observed. Carbapenem therapy was associated with fewer adverse events compared to therapy with other antibiotics (OR 0.79, 95% CI [0.65; 0.97], p = 0.022).
CONCLUSION
There is currently no evidence that carbapenem antibiotics are superior in terms of mortality, and success or failure for the treatment of complicated intra-abdominal infections (secondary peritonitis). The rate of adverse events is lower under carbapenem therapy compared to control antibiotics.
TRIAL REGISTRATION
PROSPERO 2018 CRD42018108854.
Identifiants
pubmed: 36949237
doi: 10.1007/s11605-023-05651-7
pii: 10.1007/s11605-023-05651-7
pmc: PMC10267009
doi:
Substances chimiques
Anti-Bacterial Agents
0
Carbapenems
0
Types de publication
Systematic Review
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1208-1215Informations de copyright
© 2023. The Author(s).
Références
Intensive Care Med. 2019 Dec;45(12):1703-1717
pubmed: 31664501
Drugs. 2007;67(7):1027-52
pubmed: 17488146
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Ann Surg. 2003 Feb;237(2):235-45
pubmed: 12560782
Ann Surg. 2001 Jan;233(1):79-87
pubmed: 11141229
Antimicrob Agents Chemother. 1992 Dec;36(12):2766-73
pubmed: 1336347
Med Sci (Basel). 2017 Dec 21;6(1):
pubmed: 29267233
Antimicrob Agents Chemother. 1998 Nov;42(11):2966-72
pubmed: 9797234
Clin Infect Dis. 2010 Jan 15;50(2):133-64
pubmed: 20034345
Medicine (Baltimore). 2019 Oct;98(40):e17436
pubmed: 31577763
Infection. 1996 Nov-Dec;24(6):473-9
pubmed: 9007598
Clin Infect Dis. 1997 Feb;24 Suppl 2:S197-206
pubmed: 9126694
BMJ. 2018 Jun 18;361:k1407
pubmed: 29914871
Eur J Med Res. 2011 Mar 28;16(3):115-26
pubmed: 21486724
Eur J Clin Microbiol Infect Dis. 1993 Jun;12(6):449-53
pubmed: 8359165
BMC Gastroenterol. 2013 Apr 30;13:76
pubmed: 23631512
Surg Clin North Am. 2006 Dec;86(6):1323-49
pubmed: 17116451
J Antimicrob Chemother. 2013 May;68(5):1183-92
pubmed: 23391714
JAMA. 2013 Apr 17;309(15):1573-4
pubmed: 23592085
Int J Antimicrob Agents. 2019 Dec;54(6):790-797
pubmed: 31284041
Ann Surg. 1987 Mar;205(3):271-5
pubmed: 3548611
Open Forum Infect Dis. 2019 Sep 09;6(10):ofz394
pubmed: 31660356
Scand J Infect Dis. 1996;28(5):513-8
pubmed: 8953684